相关实验视频

Updated: Feb 3, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

[癌症治疗中II型免疫反应的研究进展]

Yunfei Dong¹, Ying Sun¹, Hongqian Guo¹

¹Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

|February 1, 2026

概括

第二种类型的免疫反应在癌症免疫中具有双重作用,可能促进或抑制瘤生长. 了解这种悖论是开发针对瘤微环境的新型癌症免疫疗法的关键.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

目前针对I型免疫的癌症免疫疗法在固体瘤中有效性有限.
由T辅助2 (Th2) 细胞介导的II型免疫反应在瘤微环境 (TME) 中起着复杂的作用.
在TME背景下,可以确定II型免疫是否促进瘤进展或具有抗瘤作用.

研究的目的:

系统地审查二型免疫反应在瘤免疫中的双重功能.
探索II型免疫的转化潜力,用于下一代癌症免疫疗法.

主要方法:

关于癌症II型免疫反应的最新研究的综述.
分析细胞因子信号通路 (例如IL-4,IL-5,IL-33) 和免疫细胞相互作用 (例如Th2细胞,巨细胞,Tfh细胞,CD8+T细胞,乙氨基).
检查II型免疫和免疫检查点阻塞 (ICB) 治疗之间的相互作用.

主要成果:

二型免疫可以通过IL-4/STAT6信号传递和M2巨细胞极化促进瘤进展,通过PD-1/PD-L1轴增强免疫抑制.
二型因子也可以通过激活细胞毒性T淋巴细胞 (CTLs) 来调解抗瘤效应.
联合ICB疗法通过刺激IL-4和IL-5的产生,促进CD8+T细胞反应和透,利用II型免疫力.

结论:

第二种类型的免疫反应在癌症中表现出一种矛盾的作用,它既是瘤免疫的驱动因素,又是瘤免疫的抑制因素.
针对II型免疫提供了增强当前癌症免疫疗法的有效性有前途的途径.
对II型免疫的免疫调节机制的进一步研究对于开发有效的癌症治疗是至关重要的.

更多相关视频

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

相关概念视频

Humoral Immune Responses

Humoral Immune Responses

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...